Organon Gestione

Gestione criteri di controllo 3/4

Organon Il CEO è Kevin Ali, nominato in Jun2021, e ha un mandato di 3.42 anni. la retribuzione annua totale è $ 14.83M, composta da 8.4% di stipendio e 91.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.056% delle azioni della società, per un valore di € 2.13M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.4 anni e 3.4 anni.

Informazioni chiave

Kevin Ali

Amministratore delegato

US$14.8m

Compenso totale

Percentuale dello stipendio del CEO	8.4%
Mandato del CEO	3.4yrs
Proprietà del CEO	0.06%
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kevin Ali rispetto agli utili di Organon?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$15m	US$1m	US$1b
Sep 30 2023	n/a	n/a	US$585m
Jun 30 2023	n/a	n/a	US$754m
Mar 31 2023	n/a	n/a	US$746m
Dec 31 2022	US$14m	US$1m	US$917m
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	US$19m	US$1m	US$1b

Compensazione vs Mercato: La retribuzione totale di Kevin ($USD 14.83M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.97M ).

Compensazione vs guadagni: La retribuzione di Kevin è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Kevin Ali (64 yo)

3.4yrs

Mandato

US$14,832,272

Compensazione

Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Ali	CEO & Director	3.4yrs	US$14.83m	0.056% € 2.1m
Matthew Walsh	Executive VP & CFO	3.4yrs	US$5.21m	0.036% € 1.3m
Kirke Weaver	Executive VP	1.8yrs	US$3.19m	0.011% € 427.9k
Susanne Fiedler	Executive VP & Chief Commercial Officer	3.8yrs	US$3.84m	0.021% € 779.5k
Joseph Morrissey	Executive VP and Head of Manufacturing & Supply	3.4yrs	US$3.74m	0.017% € 629.4k
Rachel Stahler	Executive VP & Chief Information Officer	3.4yrs	Nessun dato	0.019% € 736.7k
Jennifer Halchak	Head of Investor Relations	3.8yrs	Nessun dato	Nessun dato
Susan O'Neal	Chief Ethics & Compliance Officer	no data	Nessun dato	Nessun dato
Rebecca Edwards	Chief Communications Officer	no data	Nessun dato	Nessun dato
Daniel Karp	Executive Vice President of Corporate Development	no data	Nessun dato	0.0075% € 284.3k
Aaron Falcione	Executive VP & Chief Human Resources Officer	3.4yrs	Nessun dato	0.013% € 479.3k
Vittorio Nisita	Executive VP & Head of Global Business Services	3.4yrs	Nessun dato	0.0096% € 363.3k

3.4yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di 7XP è considerato esperto (durata media dell'incarico 3.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Ali	CEO & Director	3.4yrs	US$14.83m	0.056% € 2.1m
Carrie Cox	Independent Chairman of the Board	3.4yrs	US$450.00k	Nessun dato
Robert Essner	Independent Director	3.4yrs	US$335.00k	Nessun dato
Rochelle Lazarus	Independent Director	3.4yrs	US$320.00k	0.00025% € 9.5k
Martha McGarry	Independent Director	3.4yrs	US$320.00k	Nessun dato
R. Alan Ezekowitz	Independent Director	3.4yrs	US$330.00k	Nessun dato
Helene Gayle	Independent Director	3.4yrs	US$320.00k	Nessun dato
Shalini Sharp	Independent Director	3.4yrs	US$345.00k	0% € 0
Philip Ozuah	Independent Director	3.4yrs	US$320.00k	Nessun dato
Cynthia Patton	Independent Director	3.4yrs	US$330.00k	Nessun dato
Grace Whiteford	Independent Director	3.4yrs	US$320.00k	0% € 0
Deborah Leone	Independent Director	3.4yrs	US$330.00k	0% € 0

3.4yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 7XP sono considerati esperti (durata media dell'incarico 3.4 anni).

Organon Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Organon & Co., Annual General Meeting, Jun 04, 2024

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon Announces Two Leadership Appointments

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022

Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon

Recent updates

Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Third quarter dividend of US$0.28 announced

Organon & Co. Revises Earnings Guidance for the Full Year 2024

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others.

Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon & Co. Affirms Revenue Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 16%

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings released: EPS: US$4.01 (vs US$3.61 in FY 2022)

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 25%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Investor sentiment deteriorates as stock falls 16%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.89 in 3Q 2022)

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.95 (vs US$0.92 in 2Q 2022)

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator

Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023

First quarter 2023 earnings released: EPS: US$0.70 (vs US$1.37 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.61 (vs US$5.33 in FY 2021)

Organon Declares Quarterly Dividend, Payable on March 16, 2023

Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost

Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer

Third quarter 2022 earnings released: EPS: US$0.89 (vs US$1.27 in 3Q 2021)

Organon & Co. Revises Earnings Guidance for the Full Year 2022

Organon & Co. to Report Q3, 2022 Results on Nov 03, 2022

Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira® Biosimilar Hadlima™

Second quarter 2022 earnings released: EPS: US$0.92 (vs US$1.70 in 2Q 2021)

Organon & Co. Declares Quarterly Dividend, Payable on September 15, 2022

Organon & Co. to Report Q2, 2022 Results on Aug 04, 2022

Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022

First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.56 in 1Q 2021)

Organon & Co. Declares Quarterly Dividend, Payable on June 16, 2022

Organon & Co. to Report Q1, 2022 Results on May 05, 2022

Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Organon & Co. Provides Earnings Guidance for Full Year 2022

Organon & Co. to Report Q4, 2021 Results on Feb 17, 2022

Samsung Bioepis Co., Ltd. and Organon & Co. announce the U.S. Food and Drug Administration accept for review the supplemental Biologics License Application

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Independent Director recently bought €87k worth of stock

Organon & Co. Declares Inaugural Quarterly Dividend, Payable on September 13, 2021